Medicinal chemistry: New chemical classes and subtype-selective ligands

Sigma Receptors: Chemistry, Cell Biology and Clinical Implications

Volumn , Issue , 2007, Pages 25-44

  Newman, Amy Hauck ^a   Coop, Andrew ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44349144023     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-36514-5_2     Document Type: Chapter

References (70)

1. Izhak Y. Sigma Receptors. Academic Press, San Diego 1994.
2. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa BR, Rice KC. sigma receptors: biology and function. Pharmacol Rev 1990, 42:355-402.
3. de Costa BR, Rothman RB, Bowen WD, Radesca L, Band L, Reid A, Paolo LD, Walker JM, Jacobson AE, Rice KC. Novel kappa opioid receptor and sigma ligands. NIDA Research Monograph 1992b, 119:76-80.
4. Martin WR, Eades CE, Thompson JA, Huppler RE. The effects of morphine- And nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976, 197:517-524.
5. May EL, Jaconson AE, Mattson MV, Traynor JR, Woods JH, Harris LS, Bowman ER, Aceto MD. Synthesis and in vitro and in vivo activity of (-)-(1R, 5R, 9R)- And (+)- (1S, 5S, 9S)-N-alkeny1-, -N-alkyny1-, and -N-cyanoalkly-5, 9-dimethyl-2'-hydroxy-6, 7- benzomorphan homologues. J Med Chem 2000, 43:5030-5036.
6. 3H]SKF 10, 047 to etorphine- inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 1982, 223:284-290.
7. 3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 1984, 81:5618-5621.
8. 3H]-1-[1- (2-thienyl)cyclohexyl]-piperidine. J Pharmacol Exp Ther 1986, 238:739-748.
9. 3H]tolyl)guanidine: A selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 1986, 83:8784-8788.
10. 3H](+)-pentazocine, a highly potent and selective radioligand for sigma receptors. FEBS Lett 1989, 251:53-58.
11. 1-binding site. Proc Natl Acad Sci USA 1996, 93:8072-8077.
12. Ronsisvalle G, Prezzavento O, Marrazzo A, Vittorio F, Massimino M, Murari G, Spampinato S. Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocinc as acylant agent for the sigma-1 receptor. J Med Chem 2002, 45:2662-2665.
13. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: Decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 1990, 527:244-253.
14. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, Su TP, Tam SW, Taylor DP. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992, 13:85-86.
15. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol Mol Pharmacol Sect 1994, 268:9-18.
16. 3H](+)-Pentazocine: A potent and highly selective benzomorphan-based probe for sigma-1 receptors. Mol Neuropharmacol 1993, 3:117-126.
17. Ablordeppey SY, Fischer JB, Burke Howie KJ, Glennon RA. Design, synthesis and binding of sigma receptor ligands derived from butaclamol. Med Chem Res 1992, 2:368-375.
18. Contreras PC, DiMaggio DA, O'Donohue TL. An endogenous ligand for the sigma opioid binding site. Synapse 1987, 1:57-61.
19. Su TP, Weissman AD, Yeh SY. Endogenous Ligands for sigma opioid receptors in the brain ("sigmaphin"): evidence from binding assays. Life Sci 1986, 38:2199-2210.
20. Neumaier JF, Chavkin C. Calcium-dependent displacement of haloperidol-sensitive sigma receptor binding in rat hippocampal slices following tissue depolarization. Brain Res 1989, 500:215-222.
21. Connor MA, Chavkin C. Focal stimulation of specific pathways in the rat hippocampus causes a reduction in radioligand binding to the haloperidol-sensitive sigma receptor. Exp Brain Res 1991, 85:528-536.
22. Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988, 240:219-221.
23. Moebius FF, Reiter RJ, Hanner M, Glossmann H. High affinity of sigma-1 binding sites for sterol isomerization inhibitors: Evidence for a pharmacological relationship with the yeast sterol C8-C7 isomerase. Br J Pharmacol 1997, 121:1-6.
24. de Costa BR, Radesca L, Paolo LD, Bowen WD. Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines. J Med Chem 1992a, 35:38-47.
25. Zhang Y, Williams W, Bowen WD, Rice KC. Synthesis and evaluation of aryl- substituted N-(arylcthyI)-N-methyI-2-( 1 -pyrrolidinyl)ethylamines and corresponding arylacetamides for sigma receptor affinity. J Med Chem 1996, 39:3564-3568.
26. Ronsisvalle G, Marrazzo A, Prezzavento O, Pasquinucci L, Vittorio F, Pittala V, Pappalardo MS, Cacciaguerra S, Spampinato S. (+)-cis-N-Ethyleneamino-N- normetazocine derivatives. Novel and selective sigma ligands with antagonist properties. J Med Chem 1998, 41:1574-1580.
27. El-Ashmawy M, Ablordeppey SY, Issa H, Gad L, Fischer JB, Burke Howie KJ, Glennon RA. Further investigation of 5-phenylpentylamine derivatives as novel sigma receptor ligands. Med Chem Res 1992:2119-2126.
28. Maeda DY, Williams W, Bowen WD, Coop A. A Sigma-1 receptor selective analogue of BD1008. A potential substitute for (+)-opioids in sigma receptor binding assays. Bioorg Med Chem Lett 2000, 10:17-18.
29. Berardi F, Loiodice F, Fracchiolla G, Colabufo NA, Perrone R, Tortorella V. Synthesis of chiral 1-[ω-(4-chlorophenoxy)alkyl]-4-methylpiperindines and their biological evaluation at sigma-1, sigma-2, and sterol Δ8- Δ7 isomerase sites. J Med Chem 2003, 46:2117-2124.
30. Bowen WD, Moses EL, Tolentino PJ, Walker JM. Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. Eur J Pharmacol 1990, 177:111-118.
31. Guitart X, Ballarin M, Codony X, Dordal A, Farre AJ, Frigola J, Merce R. E-5842. Drugs Fut 1999, 24:386-392.
32. Huang YS, Hammond PS, Whirret PR, Kuhner RJ, Wu L, Childers SR, Mach RH. Synthesis and quantitative structure-activity relationships of N-( 1 -bcnzylpiperidin-4-yl) phenylacetamides and related analogues as potent and selective sigma-1 receptor ligands. J Med Chem 1998, 41:2361-2370.
33. Huang Y, Hammond PS, Wu L, Mach RH. Synthesis and structure-activity relationships of N-( 1 -bcnzylpiperidin-4-yl)arylacctamidc analogues as potent sigma-1 receptor ligands. J Med Chem 2001, 44:4404-4415.
34. Nakazato A, Ohta K, Sekiguchi Y, Okuyama S, Chaki S, Kawashima Y, Hatayame K. Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine sigma ligands as potential antipsychotic drugs. J Med Chem 1999a, 42:1076-1087.
35. Nakazato A, Kumagai T, Ohta K, Chaki S, Okuyama S, Tomisawa K. Synthesis and SAR of 1-Alkyl-2-phenethylamine derivatives designed from N, N-d ipropy 1 -4-methoxy-3-(2-phenylethoxy)phenethylamine to discover sigma-1 ligands. J Med Chem 1999b, 42:3965-3970.
36. Bowen WD, Bertha, CM, Vilner BJ, Rice KC. CB-64D and CB-184: Ligands with high sigma-2 receptor affinity and subtype selectivity. Eur J Pharmacol 1995a, 278:257-260.
37. Maeda DY, Williams W, Kim WE, Thatcher LN, Bowen WD, Coop A. N-Arylalkylpiperidines as high affinity sigma-1 and sigma-2 receptor ligands: phenylpropylamines as potential leads for selective sigma-2 agents. Bioorg Med Chem Lett 2002, 12:497-500.
38. Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intercelluar stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 2000, 292:900-911.
39. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002, 62:313-322.
40. Crawford KW, Coop A, Bowen WD. Sigma-2 receptors regulate changes in sphingolipid levels in breast tumor cells. Eur J Pharmacol 2002, 443:207-209.
41. Bowen WD, Vilner BJ, Williams W, Bertha CM, Kuehne ME, Jaconson AE. Ibogaine and its congeners are sigma-2 receptor-selective ligands with moderate affinity. Eur J Pharmacol 1995b, 279:R1-R3.
42. Bowen WD. sigma receptors and iboga alkaloids. Alkaloids Chem Biol 2001, 56:173-191.
43. Mach RH, Vangveravong S, Huang Y, Yang B, Blair JB, Wu L. Synthesis of Nsubstituted 9-azabicyclo[3.3.1]nonan-3α- λl phenylcarbaraate analogs as sigma-2 receptor ligands. Med Chem Res 2003, 11:380-398.
44. Mach RH, Wu L, West T, Whirrett BR, Childers SR. The analgesic tropane analogue (+/-)-SM 21 has a high affinity for sigma-2 receptors. Life Sci 1999, 64:PL131-PL137.
45. Matsumoto RR, Mack AL. (+/-)-SM 21 attenuates the convulsive and locomotor stimulatory effects of cocaine. Eur J Pharmacol 2001, 417:R1-R2.
46. Sharkey J, Glen KA, Wolfe S, Kuhar MJ. Cocaine binding at sigma receptors. Eur J Pharmacol 1988, 149:171-174.
47. Menkel M, Terry P, Pontecorvo M, Katz JL, Witkin JM. Selective sigma ligands block stimulant effects of cocaine. Eur J Pharmacol 1991, 201:251-252.
48. Romieu P, Martin-Fandon R, Maurice T. Involvement of the sigma-1 receptor in the cocaine-induced conditioned place preference. Neuroreport 2000, 11;2885-2888.
49. Ujike H, Kuroda S, Otsuki S. Sigma receptor antagonist block the development of sensitization to cocaine. Eur J Pharmacol 1996, 296:123-128.
50. McCracken K, Bowen WD, De Costa BR, Matsumoto RR. Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur J Pharmacol 1999a, 370:225-232.
51. McCracken K, Bowen W, Matsumoto RR. Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur J Phamacol 1999b, 365:35-38.
52. Matsumoto RR, McCracken K, Friedman M, Pouw B, De Costa BR, Bowen WD. Conformationally restricted analogs of BD1008 and antisense oligodeoxynucleotide targeting sigma-1 receptors produce anti-cocaine effects in mice. Eur J Pharmacol 2001b, 419:163-174.
53. Matsumoto RR, McCracken K, Pouw B, Miller J, Bowen WD, Williams W, de Costa BR. N-Alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur J Pharmacol 2001c, 411:261-273.
54. 125I ) Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor. Proc Natl Aca Sci USA 1992, 89:1393-1397.
55. Wilke RA, Mehta RP, Lupardus J, Chen Y, Ruoho A, Jackson MB. Sigma receptor photolabeling and sigma-receptor-mediated modulation of potassium channels in tumor cells. J Biol Chem 1999, 274:18387-18392.
56. 3H] (+) 3-PPP to sigma receptors in rat brain. Life Sci 1990, 47:133-137.
57. Husbands SM, Izenwasser S, Loeloff RJ, Katz JL, Bowen WD, Vilner BJ, Newman AH. Isothiocyanate derivatives of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]-carbazole (rimcazole): Irreversible ligands for the dopamine transporter. J Med Chem 1997, 40:4340-4346.
58. Izenwasser S, Newman AH, Katz JL. Cocaine and several sigma receptor ligands inhibit dopamine uptake in rat caudate-putamen. Eur J Pharmacol 1993, 243:201-205.
59. Husbands SM, Isenwasser S, Kopajtic T, Bowen WD, Vilner BJ, Katz JL, Newman AH. Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-cis-3, 5-dimethyl-1-piperazinyl)-propyl]carbazole (rimcazole) analogues. J Med Chem 1999, 42:4446-4455.
60. Cao JJ, Husbands SM, Kopajtic T, Katz JL, Newman AH. [3-cis-3, 5-Dimethyl-(1- piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter. Bioorg Med Chem Lett 2001, 11:3169-3173.
61. Cao JJ, Kulkarni SS, Husbands SM, Bowen WD, Williams W, Kopajtic T, Katz JL, George C, Newman AH. Dual probes for the dopamine transporter and sigma-1 receptors: novel piperazinyl alkyl-Ws-(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. J Med Chem 2003, 46:2589-2598.
62. Matecka D, Rothman RB, Radesca L, De Costa BR, Dersch CM, Partilla JS, Pert A, Glowa JR, Woljnick FHE, Rice KC. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of piperazine ring of 1- [2(dipheny lmethoxy)ethy 1] - And 1 -[2-[bis(4-fluorophenyl)methoxy] ethyl] -4-(3 - phenylpropyl)piperazines (GBR 12936 and GBR 12909). J Med Chem 1996, 39:4704-4716.
63. Matecka D, Lewis D, Rothman RB, Dersch CM, Wojnicki FHE, Glowa JR, DeVries AC, Pert A, Rice KC. Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- And 1-[2- [bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors. J Med Chem 1997, 40:705-716.
64. Katz JL, Libby T, Kopajtic T, Husbands SM, Newman AH. Behavioral effects of rimcazole analogues alone and in combination with cocaine. Eur J Pharmacol 2003, 468:109-119.
65. Newman AH, Kulkarni S. Probes for the dopamine transporter: new leads towards a cocaine-abuse therapeutic - A focus on analogues of benztropine and rimcazole. Med Res Rev 2002, 5:429-464.
66. Matsumoto RR, Hewett KL, Pouw B, Bowen WD, Husbands SM, Cao JJ, Newman AH. Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology 2001a, 41:878-886.
67. Romieu P, Phan V, Martin-Fardon R, Maurice T. Involvement of the sigma-1 receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 2002, 26:444-455.
68. Maurice T, Martin-Fardon R, Romieu P, Matsumoto RR. Sigma-1 receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002, 26:499-527.
69. Glennon RA, Ablordeppey SY, Ismaiel AM, El-Ashmawy MB, Fischer JB, Howie KB. Structural features important for sigma-1 receptor binding. J Med Chem 1994, 37:1214-1219.
70. Ablordeppey SY, Fischer JB, Glennon RA. Is a nitrogen atom an important pharmacophoric element in sigma ligand binding? Bioorg Med Chem 2000, 8:2105-2111.